




FIG. 1




FIG. 1
(cont.)





FIG. 2



Mostrar 1 – 121 de 121 residuos:



2008-09

10

	Residuo inusual (<1 % de secuencias)	Insersión	Sitio de fosforilación de TYR KIN previsto	Sitio de fosforilación de PKC previsto
				
				
				
				



		<-----FR1-IMG1-----><-----CDR1-IM
		W V Q L V E T G G G L I Q P G R S L R L S C A A S G F T F S
		CAGGTGCAGCTGGTGGAGACTGGAGGAGGCTTGATCAGCTGGGAGGTCCCTGAGACTCTCTGTGGAGCCTTGATTCACCTTCAGT
1	Query_1	90
V 95,6 % (283/296)	IGHV3-30*04	90
		Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S
		T.....G.....G.....G.....
1	IGHV3-30-1*01	90
V 95,6 % (283/296)	IGHV3-30-1*01	90
V 95,6 % (283/296)	IGHV3-30-3*03	90
95,6 % (283/296)	KY198812	90
95,6 % (283/296)	KY198822	90
95,6 % (283/296)	KY198884	90
95,6 % (283/296)	KY198943	90
95,6 % (283/296)	K0134255	90
		GT-----><-----FR2-IMG1-----><-----CDR2-IMG1-----><-----
		S Y A N H W V R Q A P G K G L E W V A V I S Y A G E V K Y Y
91	Query_1	180
V 95,6 % (283/296)	IGHV3-30*04	180
		AGCTATGCTATGCACTGGTCCGCGAGGCTCCAGGCAAGGAGCTGGAGTGGGTGGCAGTTATATCATATGCGGAGGAGGAGTGAATACTAC
		AT..AAGTAAT,.....
91	IGHV3-30-1*01	180
V 95,6 % (283/296)	IGHV3-30-1*01	180
V 95,6 % (283/296)	KY198812	180
95,6 % (283/296)	KY198822	180
95,6 % (283/296)	KY198884	180
95,6 % (283/296)	KY198943	180
95,6 % (283/296)	K0134255	180

FIG. 3B

Mostrar 1 – 110 de 110 residuos:

S	C	S	G	S	S	S	N	M	G	R	R	P	V	N	W	Y	Q	Q	I	P	Q	T
L23	L23	L24	L25	L26	L27	L28	L29	L30	L30A	L30B	L31	L32	L33	L34	L35	L36	L37	L38	L39	L40	L41	L42

Q	S	Q	T	S	A	S	L	T	I	S	Q	L	Q	S	E	D	E	A	E	V	F	C
1.66	1.67	1.68	1.69	1.70	1.71	1.72	1.73	1.74	1.75	1.76	1.77	1.78	1.79	1.80	1.81	1.82	1.83	1.84	1.85	1.86	1.87	1.88

A	V	D	I	G	R	V	L	Q	L	G	G	T	Q	L	A	V	L			
L89	L90	L91	L92	L93	L94	L95	L95A	L95B	L96	L97	L98	L99	L100	L101	L102	L103	L104	L105	L106	L106A

Sitio de amidación de PKC previsto
 Sitio de fosforilación de CK2 previsto
 Inserción
 Residuo inusual (<1 % de secuencias)

FIG. 4A

			-----FR3-IMG7-----><-----	
			D R F S G S Q S G T S A S L T I S G L Q S E D E A E Y F C A	270
			GACCGATTCTCTGGCTCCAGTCTGGGACCTCAGGCTCCCTGACCATCAGTGGGCTCCAGTCTGGGATGAGGCTGATATTCTGTGCA	270
			A.....G.....T.....A.....	
V 92,9 % (263/283)	Query_1	181	D R F S G S K S G T S A S L A I S G L Q S E D E A D Y Y C A	270
	IGLV1-44*01	181	A.....G.....T.....A.....	
			A.....G.....C.....T.....A.....	270
V 91,5 % (259/283)	IGLV1-47*02	181	A.....G.....C.....T.....A.....	270
V 91,2 % (258/283)	IGLV1-47*01	181	A.....G.....T.....A.....	270
93,6 % (265/283)	A2408472	181	A.....G.....T.....A.....	270
93,3 % (263/282)	A2578382	180	A.....G.....T.....A.....	269
92,9 % (263/283)	AC253551	33253	A.....G.....T.....A.....	33164
92,9 % (263/283)	K0067746	181	A.....G.....T.....A.....	270
92,9 % (263/283)	KT304592	181	A.....G.....T.....A.....	270
			-----CDR3-IMG7----->	
			V W D D I G R V L Q L G G G T Q L A V L	
			GTTTGGGATGACATCGGCTCCGCTCTGAGTTAGGCGGAGGACCCAGCTGGCTGCTTA	330
			.CA.....	283
			A W D D	
			.CA.....	283
			.CA.....	283
			C..A.....A.....	36
			C.....G...A...A.....	37
			C..A.....A...C...~	36
			.CA.....	283
			.CA.....	282
			.CA.....	33163
			.CA.....	283
			.CA.....	283

			-----CDR3-IMG7----->	
			V W D D I G R V L Q L G G G T Q L A V L	
			GTTTGGGATGACATCGGCTCCGCTCTGAGTTAGGCGGAGGACCCAGCTGGCTGCTTA	330
			.CA.....	283
			A W D D	
			.CA.....	283
			.CA.....	283
			C..A.....A.....	36
			C.....G...A...A.....	37
			C..A.....A...C...~	36
			.CA.....	283
			.CA.....	282
			.CA.....	33163
			.CA.....	283
			.CA.....	283

FIG. 4B Cont.

Comparación de unión




FIG. 6A





FIG. 6B

Categoría		AZD2936
Formato biespecífico:	DuetMab	
Isotipo Fc		IgG1-TM humana
Brazo PD-1		LO115
Brazo TIGIT		VAR1
K _D a PD-1	Humano	0,4 nM
	Cyno	0,3 nM
K _D a TIGIT	Humano	15 pM
	Cyno	41 nM




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11 B




FIG. 11 A




FIG. 11C

FIG. 11D

Inhibición del crecimiento tumoral de OE21

Donante 198165




FIG. 12A

Donante 148026




FIG. 12B

Inhibición del crecimiento tumoral de OE21




FIG. 12D




FIG. 12C

Inhibición del crecimiento tumoral de PC9-MART1




FIG. 13A

FIG. 13B

Inhibición del crecimiento tumoral de PC9-MART1

**Donante 158741: 24 horas
después de la segunda dosis**




FIG. 13C

**Donante 154763: 24 horas
después de la segunda dosis**




FIG. 13D




FIG. 14A




FIG. 14B




FIG. 15